Business
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
Press Release CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection depth with ZENEO® matches that of 30-mm conventional intramuscular needles, out-performs length of needles imbedded in commercially available needle-based auto-injectors.ZENEO® further demonstrates commercial adoption potential by eliminating usage errors and mimicking traditional intra
About this update from Crossject Sa
[{"type":"image","alt":"CROSSJECT","displaySize":"","headline":null,"caption":"CROSSJECT","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rK9m607pcnIrkhBB4D_IFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a","width":200,"height":87}},"lazy":false},{"type":"text","content":"Press Release","length":13,"tagName":"p"},{"type":"text","content":"CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors","length":188,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Injection depth with ZENEO® matches that of 30-mm conventional intramuscular needles, out-performs length of needles imbedded in commercially available needle-based auto-injectors.","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"ZENEO® further demonstrates commercial adoption potential by eliminating usage errors and mimicking traditional intramuscular injection.","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"Dijon, France 15 May, 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in the advanced phases of development and registration of ZEPIZURE®, an emergency injectable for the management of epilepsy crises, announces excellent results for its proprietary ZENEO® auto-injector in its last Magnetic Resonance Imaging (MRI) depth validation study. The study included the precise monitoring of the pathway of the injected solution from skin to muscle, demonstrated, once again, a high reliability and consistent dose delivery with the intramuscular configuration of the ZENEO® needle-free auto-injector.","length":643,"tagName":"p"},{"type":"text","content":"“These excellent results have shown that the ZENEO® auto-injector reaches the required depth as efficiently as a conventional 30-mm needle. The study firmly supports the clinical value of ZENEO® for use in emergency and rescue situations. Moreover, the performance of the ZENEO® device exceeded the needle length o...